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Abstract
Neural stem cells are activated within neurogenic niches in response to brain injuries. This results in the production of
neuroblasts, which unsuccessfully attempt to migrate toward the damaged tissue. Injuries constitute a gliogenic/non-
neurogenic niche generated by the presence of anti-neurogenic signals, which impair neuronal differentiation and
migration. Kinases of the protein kinase C (PKC) family mediate the release of growth factors that participate in
different steps of the neurogenic process, particularly, novel PKC isozymes facilitate the release of the neurogenic
growth factor neuregulin. We have demonstrated herein that a plant derived diterpene, (EOF2; CAS number 2230806-
06-9), with the capacity to activate PKC facilitates the release of neuregulin 1, and promotes neuroblasts differentiation
and survival in cultures of subventricular zone (SVZ) isolated cells in a novel PKC dependent manner. Local infusion of
this compound in mechanical cortical injuries induces neuroblast enrichment within the perilesional area, and
noninvasive intranasal administration of EOF2 promotes migration of neuroblasts from the SVZ towards the injury,
allowing their survival and differentiation into mature neurons, being some of them cholinergic and GABAergic. Our
results elucidate the mechanism of EOF2 promoting neurogenesis in injuries and highlight the role of novel PKC
isozymes as targets in brain injury regeneration.
Introduction
Brain injuries of different etiologies, produce sensory-
motor alterations and irreversible cognitive deficits1. No
effective treatments to compensate neuronal loss have
been found so far. However, the discovery of neurogen-
esis in the adult brain revealing the capacity of the brain
to generate new neurons from neural stem cells (NSC)
has opened a door to new therapies to effectively treat
this type of disorders. Adult neurogenesis occurs under
physiological conditions in the dentate gyrus of the hip-
pocampus (DG) and the subventricular zone (SVZ)2,3.
These regions also react to an injury activating NSC to
produce neural progenitor cells (NPC), stimulating pro-
liferation and differentiation of NPC into neuroblasts,
and altering migration patterns of these neuroblasts to
lead them towards the injured area4–6. However, only a
very small number of newly born neurons reach the
lesion7–9. This is a consequence of the release of
inflammatory signals that create a gliogenic/non-neuro-
genic environment within the injured tissue10. For
example, ligands of the epidermal growth factor receptor
(EGFR) in injuries promote gliogenesis and impair
migration of neuroblasts towards injuries11. On the
contrary, inhibition of EGFR ligand release facilitates
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neurogenesis in injuries12–14. Transforming growth fac-
tor alpha (TGFα), and other EGFR ligands are synthe-
sized as precursor membrane anchored proteins, which
are secreted upon the metalloprotease-catalyzed proteo-
lysis of the soluble, active ectodomain. ADAM17 is the
main convertase involved in the ectodomain shedding of
TGFα and other EGFR ligands15–17. However, ADAM17
also catalyzes the proteolysis of ligands, that activate
other receptors of the ErbB family such as neuregulins.
The selectivity of this enzyme for each ligand governs
ligand release and it is determined by phosphorylation
reactions within the cytoplasmic domain of the pro-
ligand molecules, catalyzed by kinases of the protein
kinase C (PKC) family18. PKCα activated by phorbol-12-
myristate-13-acetate (PMA) catalyzes the phosphoryla-
tion of TGFα, amphiregulin and HB-EGF precursors
facilitating their ADAM17-mediated shedding. On the
contrary, activation of novel PKCδ is required for
ADAM17-mediated secretion of neuregulin 1
(NRG1)18,19. Neuregulin-mediated activation of ErbB4
favors neurogenesis in the adult brain promoting neu-
roblast survival and organizing migration of neuroblasts
from the SVZ towards the olfactory bulb20,21. Consider-
ing these findings, it seems reasonable to hypothesize that
specific activation of different PKC isozymes would alter
the pattern of growth factor secretion within neurogenic
niches, and will regulate either proliferation—mediated
by classical PKCβ and α22—or neuroblast survival and
migration—mediated by novel PKC isozymes23. Conse-
quently, in order to promote neurogenesis in injuries, it
would be useful to find molecules with the capacity to
activate novel PKC specifically facilitating neuregulins
release. Such molecules would probably promote differ-
entiation of NPC into newborn neurons and enable
neuroblasts migration from neurogenic areas towards
injuries.
Results
The diterpene with lathyrane structure EOF2 activates PKC
without promoting proliferation
The lathyrane EOF2 (CAS number 2230806-06-9) was
previously described by our group as a diterpene with no
effect on NPC proliferation22. Since other diterpenes
induced proliferation of NPC24 via classical PKC activa-
tion23, we analyzed its capacity to activate PKC and to
facilitate the generation of neurospheres. Although EOF2
treatment increased PKC activity by twofold in neuro-
sphere cultures (supplementary fig. S1 D), it exerted no
change in the size of the neurospheres and a reduction in
the number of neurospheres generated. Given its capacity
to activate PKC without inducing proliferation, it was
possible that EOF2 specifically activated novel PKC
without affecting the classical isozymes—reported as
responsible of the proliferative effect22.
EOF2 facilitates NRG1 release
In order to determine whether EOF2 specifically
induced neuregulin release, we used protein constructs in
which NRG1 was fused to mCherry in the N-terminal and
eGFP in the C-terminal (mCherry-NRG1-eGFP) (Fig. 1A)
according to the work of Kamezaki et al. with modifica-
tions25. A similar construct was used to test TGFα release
(mCherry-TGFα-eGFP) (Fig. 2A). We tested the effect of
EOF2 in HEK293T cells transfected with the constructs.
As shown in supplementary table T1, HEK293T cells
express the mRNAs encoding for PKC isozymes involved
in neuregulins and TGFα release as well as ADAM17
protein, validating them as a model to test the release of
the above-mentioned growth factors.
NRG1 release was measured as explained in M&M
section. As shown in Fig. 1 the red/green ratio in
HEK293T transfected with mCherry-NRG1-eGFP and
treated with vehicle (none) did not vary with time
(Fig. 1B, C) (supplementary movie 1), indicating that in
the absence of a PKC-stimulating compound this ligand
was not released. However, the addition of EOF2 induced
a progressive reduction of this ratio (Fig. 1B, C) (supple-
mentary movie 2), suggesting that this compound was
facilitating the mCherry-labeled ectodomain shedding of
neuregulin. Interestingly, these changes in color ratio
were prevented by addition of the general PKC inhibitor
Gö6850 to the culture medium (at a final concentration of
1 µM), 30 min before the beginning of the treatment with
EOF2 (Fig. 1B, C) (supplementary movie 3). In order to
uncertain the role that novel PKC played in this effect, we
added the classical PKC inhibitor Gö6976 (at a final
concentration of 1 µM), 30 min before the addition of
EOF2 to mainly inhibit classical PKC. Results show a
reduction in the red/green ratio even in the presence of
the inhibitor, indicating that the effect on neuregulin
release was mediated by novel PKC activation (Fig. 1A–C)
(supplementary movie 4).
Furthermore, we analyzed the levels of mCherry signal
in the culture medium of HEK293T cells transfected
with the mCherry-NRG1-eGFP construct and treated
with EOF2, vehicle, or EOF2+Gö6850. 30, 60, and
180 min after the treatment cells were separated from
the culture medium and mCherry fluorescence was
measured in a fraction of 50 µL of medium (total volume
of medium 1mL) as a ratio of the GFP fluorescence
remaining inside the cells. The red/green ratio in con-
trol cultures (non-treated transfected cells) at all time
points was considered as 100% (Fig. 1D dashed line). A
time-dependent increase in the red/green fluorescence
ratio was observed in the culture medium upon treat-
ment with EOF2. This was not observed in cultures
treated with EOF2+Gö6850 (Fig. 1D).
In order to analyze whether EOF2 specifically facilitated
the shedding of NRG1, and had no effect on TGFα, we
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used the construct mCherry-TGFα-eGFP (Fig. 2A)
transfected into HEK293 treated with EOF2. (Fig. 2B, C).
Time-lapse imaging experiments showed no reduction in
the red/green ratio upon treatment with either vehicle or
EOF2 (supplementary movies 5–6), whereas a time
dependent reduction was observed with the pan-PKC
activator PMA (supplementary movie 7). Likewise, no
alteration of the red/green ratio was observed when
mCherry was measured in the culture medium of
mCherry-TGFα-eGFP transfected cells at different time
points (Fig. 2D).
EOF2 facilitates neuronal differentiation of SVZ isolated
progenitors in vitro
To elucidate whether EOF2 played a role in neurogen-
esis, we tested the capacity of this compound to induce
neuroblast enrichment in cultures of SVZ-isolated cells
under differentiation conditions. Cells were cultured
attached onto a substrate in the absence of growth factors
and left for 72 h to differentiate in the presence and
absence of EOF2. The percentage of neuroblasts (β-III-
tubulin+) and glial cells (GFAP+) was quantified. In
control cultures the percentage of GFAP+ cells and β-III-
tubulin+ cells were similar (Fig. 3A–D). Treatment of
cultures with EOF2 increased the percentage of β-III-
tubulin+ cells in almost twofold (Fig. 3A–B), whereas the
percentage of GFAP+ cells remained unchanged (Fig.
3A–C). In addition, a small reduction in the number of
nonviable cells in cultures treated with EOF2 was
observed (Fig. 3D), suggesting an additional role for EOF2
in promoting survival.
EOF2-induced differentiation of SVZ isolated progenitors
in vitro is mediated by novel PKC
We next study the expression patterns of the classical
and novel PKC isozymes in cultures of attached SVZ
isolated cells. Classical PKCβ and novel PKCθ, were the
most abundant followed by classical PKCα and novel
PKCε. Almost undetectable levels of classical PKCγ or
novel PKCδ and PKCη were observed (Fig. 4A). There-
fore, we analyzed whether blocking the expression of the
most abundant novel PKCθ reverted the effect of EOF2.
Attached SVZ isolated cells were cultured in the absence
of growth factors and transfected with a siRNA to inter-
fere with PKCθ expression as previously described26. Cells
were left for 72 h in the presence and absence of EOF2
and the percentage of neuroblasts and glial cells was
quantified. The elevated percentage of neuroblasts found
in the presence of EOF2 was reduced to almost control
levels in cultures in which PKCθ expression was inhibited
by the siRNA (Fig. 4B, C). EOF2 alone or in combination
with PKCθ siRNA had no effect on the percentage of
GFAP+ cells (Fig. 4B, D).
NRG1 and ErbB4 expression in brain injuries
In attempt to understand whether this differentiating
compound could be used to promote neurogenesis in
injuries, we analyzed the expression of neuregulin and its
receptor ErbB4 within the perilesional area and in the
adjacent SVZ in response to an injury. We performed
mechanical cortical injuries in mouse brains and 14 days
post injury (dpi) the expression of neuregulin and ErbB4
in the injury and in the ipsilateral SVZ was analyzed by
real time qPCR. The expression of NRG1 did not change
between the ipsilateral and contralateral side (Supple-
mentary Fig. S2 B) neither within the injury or the SVZ.
However, a twofold increase in ErbB4 expression was
found in the ipsilateral SVZ (supplementary Fig. S2 A).
Local infusion of EOF2 in brain injuries enhances the
number of neuroblasts
We next analyzed whether EOF2 infusion in brain
injuries facilitated the generation of neuroblasts and
neurons within the perilesional area. Mechanical inju-
ries in the motor cortex of mouse brains were performed
and EOF2 was locally infused by implanting osmotic
minipumps releasing EOF2 or vehicle for 2 weeks. BrdU
was injected on the day of sacrifice (Fig. 5A). Treatment
(see figure on previous page)
Fig. 1 Real-time imaging of the EOF2 induced ectodomain shedding of Cherry-NRG1-GFP. a Schematic representation of the mCherry-NRG1-
GFP construct and mechanism of action. b Images of mCherry-NRG1-GFP expressing, serum-starved HEK293T cells stimulated with diluent, EOF2
(5 µM), EOF2 plus the general PKC inhibitor Gö6850 (5 µM) and EOF2 plus the classical inhibitor of PKC Gö6976 (1 µM) during 180 min. PKC inhibitors
were added 30min before EOF2. mCherry/GFP ratio images at the indicated time points are shown in the intensity modulated display-mode. The
color range goes from red to blue to represent mCherry/GFP ratios. The upper and lower limits of the ratio range are shown on the right. Scale bar
represent 20 µm. c Quantitative analysis of the microscopic images obtained from the time-lapse assays of HEK293T cells expressing Cherry-NRG1-
GFP. mCherry/GFP ratios were normalized to the average mCherry/GFP ratio measured before stimulation. The mean normalized mCherry/GFP ratios
and SEM are shown, n= 40. See also supplementary movie 1. d Fluorescence analysis of m-Cherry in the culture medium of HEK293T cells
transfected with the construct mCherry-NRG1-GFP as a ratio of GFP fluorescence in the cellular fraction. mCherry signal in the culture medium of
transfected HEK293T cells was measured in a fluorimeter as described in the Material and Methods section. Bars represent the ratio red:green in
transfected cells at different time points after treatment with EOF2 or EOF2+ PKC inhibitor Gö6850. Values are given as a percentage of the red:green
ratio in non-treated transfected cells (dashed line). Data are the mean values ± S.E.M of nine independent measurements (n= 9). Statistical analysis:
two tailed unpaired Student’s t test (*EOF2 vs control at 60 min, p= 0.0456; ****EOF2+ Gö6850 vs control at 30 min, p < 0.0001; EOF2 vs control at
180 min, p < 0.0001).
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had no effect on the extent of the injury or on the size of
the perilesional area, in control and treated groups
(inter-animal differences: 30 ± 4 × 103 µm2/section). The
number of BrdU+ cells in the perilesional area of mice
treated with either vehicle or EOF2 for 14 dpi was
similar between the two groups (Fig. 5B, C). Neuroblasts
within the peri-lesional area of control mice were hardly
visible. Interestingly, the number of neuroblasts
Fig. 2 (See legend on next page.)
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increased dramatically in mice treated with EOF2 (Fig.
5B, D–F).
Local infusion of EOF2 in brain injuries reduces the number
of glial cells
We next analyzed the number of BrdU+ cells that
expressed the glial marker GFAP in both control and
EOF2 treated mice, as well as the area occupied by glial
cells as a measure of gliosis and glial scar. Noticeable, the
GFAP burden was significantly reduced in injuries treated
with EOF2 compared with controls (Fig. 6A–D).
Accordingly, the percentage of BrdU+ cells that co-
localized with the glial cell marker GFAP was also reduced
in treated injuries (Fig. 6A–C). This suggested a role for
EOF2 in reducing gliosis around the injured area (Fig. 6A,
B). No effect of the treatment was observed on the
number of nestin+ undifferentiated progenitors or in its
proliferation rate (Fig. 6B, E, F).
Local treatment of injuries with EOF2 did not affect
neurogenesis in the SVZ or DG
It was then tested whether local treatment with EOF2
affected neurogenesis in the SVZ and DG. We analyzed
BrdU+, BrdU+/DCX+ BrdU+/GFAP+, and BrdU+/
nestin+ cells in both the SVZ and DG. As expected, in
response to the injury, the number of BrdU+ cells was
significantly increased in the ipsilateral SVZ (supple-
mentary fig. S3 A–F) and DG (supplementary fig. S4 A–F)
of control and EOF2-treated mice compared with the
contralateral areas, indicating the presence of a pro-
liferative response to the injury. However, no effect of
EOF2 was observed on the proliferation of progenitor
cells and their progeny in the two neurogenic niches
(supplementary figs. S3 and S4 A–F).
Intranasal administration of EOF2 facilitates neuroblast
migration towards the perilesional area
In order to test whether neuroblast found in EOF2
treated mice had migrated from the adjacent SVZ, we had
to find a method of administration that allowed EOF2 to
reach neurogenic regions. In addition, used a BrdU
labeling approach that allowed BrdU to incorporate in
proliferating cells of the SVZ before performing the
injury. Thus, healthy mice were injected with BrdU for
three consecutive days and left for another 3 days for the
BrdU to be cleared. By using this strategy, only pro-
liferating cells in neurogenic niches were labeled with
BrdU. Then, mice were injured and treated for 14 days
with daily intranasal administrations of EOF2 or vehicle
(Fig. 7A). Mice were sacrificed 14 dpi and the co-
localization of BrdU with DCX, and GFAP was quantified.
Interestingly, BrdU+ cells were only detected within the
perilesional area of mice treated with EOF2 (Fig. 7B, C).
Also, we were able to find a significant amount of DCX+
neuroblasts that were not present within the perilesional
area of control mice (Fig. 7B, D). BrdU+ cells were GFAP+
or DCX+ (Fig. 7B, E–G). Despite the presence of BrdU+/
GFAP+ cells in treated mice, no effect on the GFAP
burden was observed in treated mice compared with
control (Fig. 7H). The analysis of BrdU+ cells in the SVZ
shows a large reduction in the number of BrdU+ cells in
the ipsilateral SVZ of both control and EOF2 treated mice
in comparison with their contralateral SVZ (supplemen-
tary fig. S5). Moreover, EOF2 treated mice showed a
smaller number of BrdU+ cells in the SVZ than their
control counterparts (supplementary fig. S5). In addition,
we have observed that neuroblasts migrated from the SVZ
of EOF2 treated mice towards the injury through orga-
nized migratory pathways that described a track from the
SVZ towards the injury through the corpus callosum
reaching the lesioned area (supplementary fig. S6). This
was not observed in control mice.
In addition, only EOF2-treated mice showed mature
NeuN+ neurons that had incorporated BrdU within the
perilesional area (Fig. 8A, B–D). Accordingly, a larger
number of mature neurons were quantified within the
perilesional area of EOF2-treated mice 14 dpi (Fig. 8B, C).
We next use a longer treatment (28 days) that allowed
(see figure on previous page)
Fig. 2 Real-time imaging of the EOF2 induced ectodomain shedding of Cherry-TGFα-GFP. a Schematic representation of the mCherry-TGFα-
GFP construct and mechanism of action. b Images of mCherry-TGFα-GFP expressing, serum-starved HEK293T cells stimulated with diluent, EOF2
(5 µM) or PMA (5 µM) during 180. mCherry/GFP ratio images at the indicates time points are shown in the intensity modulated display-mode. The
colors range goes from red to blue to represent mCherry/GFP ratios. The upper and lower limits of the ratio range are shown on the right. Scale bar
represent 20 µm. c Quantitative analysis of mCherry/GFP ratios in HEK293T cells expressing Cherry-TGFα-GFP. mCherry/GFP ratios were normalized to
the average mCherry/GFP ratio measured before stimulation. The mean normalized mCherry/GFP ratios and SEM are shown, n= 40. See also
supplementary movie 2. d Fluorescence analysis of m-Cherry in the culture medium of cells transfected with the fusion protein construct mCherry-
TGFα-GFP as a ratio of GFP fluorescence in the cellular fraction. mCherry signal in the culture medium of transfected HEK293T cells was measured in a
fluorimeter as described in the Material and Methods section. Bars represent the ratio red:green in transfected cells at different time points after
treatment with EOF2 or EOF2+ PKC inhibitor Gö6850 as a percentage of the red:green ratio in non-treated transfected cells (dashed line). Cells were
treated with the EOF2 at the indicated times. Data are the mean values ± S.E.M of nine independent measurements (n= 9). Statistical analysis: two
tailed unpaired Student’s t test: (*PMA vs control at 60 min p= 0.0403; *PMA vs control at 180 min p= 0.0112).
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neuroblasts to further differentiate maintaining the BrdU
labeling protocol. We analyzed the number of BrdU+ cells
within the perilesional area after a 28-day treatment and
assessed their capacity to differentiate into mature neu-
rons of different phenotypes. We found that the number
of BrdU+ cells 28 dpi was reduced by 50% (supplementary
fig. S7 A–C) compared with 14 pdi. Almost 35% of the
BrdU+ cells co-localized with Choline acetyl transferase
(ChAT+) (supplementary fig. S7 A, D) and around 5% co-
localized with parvalbumin (supplementary fig. S7 B–D)
indicating that some of the new neurons had differ-
entiated into cholinergic and GABAergic neurons.
Discussion
We have studied in here the neurogenic effect of a small
molecule, the diterpene with lathyrane skeleton EOF2.
Unlike other lathyranes, EOF2 does not promote pro-
liferation of NPC22. However, we have demonstrated that
it specifically facilitates novel PKC-mediated NRG1
release, without affecting TGFα release. This molecule
promotes neuronal differentiation of NPC in vitro in a
novel PKC dependent manner. Moreover, EOF2 in vivo
enables migration of neuroblasts from neurogenic areas
towards an injury leading to neuroblast and neuron
enrichment in damaged brain regions.
Fig. 3 EOF treatment promotes differentiation of NPC to neurons. a Representative fluorescence microphotographs of SVZ-derived cultured
NPC that had been treated with either diluent (control) or EOF2 (5 µM). Cells were grown without growth factors and allowed to differentiate for 72 h
after treatment and then fixed. β-III-tubulin marker was used for neuronal immunodetection (red) and glial cells were identified by the
immunodetection of GFAP (green). Total nuclei were counterstained with DAPI (blue). Scale bar= 50 µm. b Graph represents the percentage of total
cells (detected by DAPI nuclear staining) that were positive for β-III-tubulin expression expressed as percentage of control. Data are the means ±
S.E.M.; n= 9 independent values (n= 9). Statistical analysis: *p= 0.0025 in unpaired two tailed Student’s t test comparing with the control group. c
Graph represents the percentage of total cells (detected by DAPI nuclear staining) that were positive for GFAP expression expressed as percentage of
control. Data are the means ± S.E.M. of nine independent values (n= 9). d Graph represents the percentage of nonviable cells after treatment as a
percentage of total cells (detected by DAPI nuclear staining) expressed as a percentage of control. Viability was measured by trypan blue exclusion as
described in the methods section. Results show a statistically significant increase in the percentage of β-III-tubulin+ cells whereas no change of
GFAP+ cells in the presence of EOF2. Data are the means ± S.E.M. of nine independent values (n= 9). Statistical analysis: *p= 0.0004 in unpaired two
tailed Student’s t test comparing with the control group.
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Fig. 4 EOF2 induce neuronal differentiation via PKCθ activation without affecting glia formation in NPC cultures. a Relative expression of
mRNA of the different PKC isozymes under differentiation conditions. mRNA quantification was performed by reverse transcription and real time
qPCR and using the Δct method. The mRNA for PKC were measured and normalized to the levels of 18S rRNA. Data are means ± S.E.M. of five
independent measurements. b Representative fluorescence microphotographs of neurosphere-derived adhered cells transfected with PKCθ siRNA, a
combination of PKCθ siRNA and EOF2 or either mock (control). Neuronal cells were identified by the immunocytochemical detection of β-III-tubulin
(red); glial cells are identified by the immunocytochemical detection of GFAP (green) and total nuclei were counterstained with DAPI (blue). Scale bar
= 50 µm. c Graph represents the percentage of total cells (detected by DAPI nuclear staining) that were positive for β-III-tubulin expression after
treatments expressed as the percentage of control. Data are the means ± S.E.M. of nine independent measurements (n= 9). Statistical analysis: two
tailed unpaired Student’s t test of each condition compared with control (*p= 0.003 and #p= 0.029). d Graph represents the percentage of total cells
(detected by DAPI nuclear staining) that were positive for GFAP expression after treatment expressed as the percentage of the control. Data are the
means ± S.E.M. of nine independent measurements (n= 9).
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Fig. 5 Local administration of EOF2 induces neuronal differentiation in the injured cortex. a Scheme of experimental procedures. Mechanical
cortical lesions were unilaterally performed in the primary motor cortex of adult mice, and osmotic minipumps were implanted to locally deliver
vehicle or EOF2 (5 µM) for 14 days. All mice were intraperitoneally-injected with BrdU on the last day of treatment as described in methods.
b Representative confocal microphotographs of the area surrounding cortical lesion in mice brain showing immnunodetection for BrdU (upper
panels) Doublecortin (DCX; medium panels) and the merged signals (lower panels). Scale bar represent 50 µm in low magnification images and
20 µm in high magnification images. The dotted line indicates the limit of the lesion (L). c Microphotograph showing details about the injury and the
lesion area. In each section, the positive cells labeled with the different markers were quantified in the peri-lesional area that corresponds to 200 µm-
wide band of tissue surrounding the lesion border. Scale bar represent 1 mm in low magnification images and 200 µm in high magnification images.
d Graph shows the number of proliferating cells labeled with BrdU per mm3 in the peri-lesional area of the indicated animal groups. Data shown are
the mean ± S.E.M.; n= 6 animals per group. e Quantification of DCX+ (doublecortin) cells per mm3 in the peri-lesional area of the indicated animal
groups. Data shown are the mean ± S.E.M.; n= 6 animals per group. Statistical analysis: *p < 0.0001 in two tailed unpaired Student’s t test comparing
EOF2 with the control. f Graph shows the percentage of BrdU+ cells that co-express the neuronal marker DCX in the peri-lesional area of the
indicated animal groups. Data shown are the mean ± S.E.M.; n= 6 animals per group. Statistical analysis: *p= 0.0320 in two tailed unpaired Student’s
t test comparing EOF2 with the control.
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Targeting neuregulin release to promote neurogenesis in
injuries
Previous reports have demonstrated the role of indivi-
dual PKC isozymes as mediators of different steps in the
neurogenic process27,28, some of them highlighting the
role of non-tumor promoting diterpenes as PKC activa-
tors that promote neurogenesis in neurogenic niches22,29.
However, neurogenic signaling molecules behave differ-
ently depending on the niche. This is the case of TGFα, a
growth factor that promotes neurogenesis in neurogenic
niches30 while inducing gliogenesis and impairing neu-
roblast migration in injuries7,11. Thus, a key step to
facilitate neurogenesis in injuries is the introduction of
neurogenic cues to counteract the gliogenic ones
generated by the injury. In this work, we have focused on
neuregulins, which are expressed in neuroblasts, and
activate TrkA receptors on neighbor cell types. The
pathways associated to these receptors promote neuro-
blast survival31. Also, neuregulin-mediated activation of
ErbB4 receptors facilitates NSC proliferation and neuro-
blast migration20,21. We searched for a compound able to
deliver neuregulins to the injured brain tissue. We chose
to study the effect of EOF2 because of its lack of effect on
stimulating NPC proliferation in a classical PKC depen-
dent manner22 and its similarity to other classical PKC
activating compounds (supplementary fig. 8). According
to the report of Newton 201832, the affinity of novel PKC
isozymes for DAG and therefore for this type of
Fig. 6 Local administration of EOF2 reduce glial differentiation in the injured cortex. Representative confocal microphotographs of the area
surrounding cortical lesion in mice brain processed for the immunohistochemical detection of the glial marker GFAP (a) and for the undifferentiated
progenitors marker nestin (b). Mechanical cortical lesions were unilaterally performed in the primary motor cortex of adult mice, and osmotic
minipumps were implanted to locally deliver vehicle or EOF2 (5 µM) for 14 days. All mice were intraperitoneally-injected with BrdU the last day of
treatment as described in methods. Scale bar represent 50 µm. The dotted line indicates the limit of the lesion (L). c Graph shows the percentage of
BrdU+ cells that co-express the glial marker GFAP in the peri-lesional area of the indicated animal groups. Data shown are the mean ± S.E.M.; n= 6
animals per group. Statistical analysis: *p= 0.0492 in two tailed unpaired Student’s t test comparing EOF2 with the control. d Graph shows the GFAP
burden, representing the glial scar, expressed as a percentage of the total lesion area. Data shown are the mean ± S.E.M.; n= 6 animals per group.
Statistical analysis: *p= 0.0310 in two tailed unpaired Student’s t test comparing EOF2 with the control. e Quantification of nestin+ cells per mm3 in
the peri-lesional area of the indicated animal groups. Data shown are the mean ± S.E.M.; n= 6 animals per group. f Graph shows the percentage of
BrdU+ cells that co-express the neural precursor marker nestin in the peri-lesional area of the indicated animal groups. Data shown are the mean ±
S.E.M.; n= 6 animals per group.
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compounds is higher than that of classical PKC isozymes
suggesting the possibility that EOF2 was a novel PKC
activating compound with no capacity to activate the
classical.
PKC isozymes participate in the release of ligands that
activate ErbB receptors25. These ligands are synthesized
and transported to the plasma membrane as transmem-
brane pro-ligands. The active soluble ligand is proteolyzed
Fig. 7 (See legend on next page.)
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from the pro-ligand and released to the extracellular
medium in a reaction catalyzed by enzymes of the ADAM
family, particularly ADAM1715. The selectivity of
ADAM17 for its substrates depends on phosphorylation
reactions on the pro-ligands catalyzed PKC kinases18,19.
Thus, phosphorylation of TGFα, HB-EGF, amphiregulin
and other EGFR ligands by classical PKC determines their
secretion, whereas, phosphorylation of NRG1 by novel
PKC isozymes facilitates its release18,19,25. We used fusion
proteins in which NRG1 and TGFα were fused to two
fluorescent probes. Similar fusion proteins had previously
been used for this particular purpose25. As time-lapse
imaging fluorescence experiments show, EOF2 induces
the shedding of NRG1 in HEK293T transfected cells, in a
time dependent manner. The release of neuregulin to the
extracellular medium was still partially observed in the
presence of a classical PKC inhibitor, which at the con-
centration required to inhibit cPKC by 80%, partially
inhibits novel PKC by 30–40%33. This indicates that the
inhibition of classical PKC does not impair NRG1 release
and suggests a role for novel PKC isozymes in the
EOF2 stimulated NRG1 release. Unfortunately, commer-
cially available specific inhibitors of novel PKC could not
be used to definitely demonstrate the role of novel PKC
isozymes in EOF2-mediated NRG1 release. EOF2 did not
induce TGFα release to the extracellular medium, indi-
cating that EOF2 specifically facilitated NRG1 release.
These results agree with previous studies showing that
PKC-δ is required for NRG1 cleavage, and that PKC-δ
phosphorylation of serine 286 in the neuregulin cytosolic
domain is essential for induced neuregulin cleavage18.
Interestingly, other reports show that classical PKC acti-
vation is required for PMA-induced cleavage of all EGFR
ligands19.
Novel PKC-mediated differentiation of NPC into
neuroblasts
EOF2 promoted neuronal differentiation of NPC
in vitro in cultures of SVZ isolated cells. This effect cor-
related with a reduction in the percentage of nonviable
cells, suggesting an effect of EOF2 on neuroblast survival
and in neuroblasts differentiation. Considering the role of
neuregulins in maintaining neuroblasts survival31, it
would be possible that EOF2-mediated neuregulin release
facilitated neuroblasts survival in our cultures. However,
an effect on NPC differentiation towards a neuronal fate is
also possible, and a combination of both effects might be
the reason for the elevated number of neuroblasts. The
effect of EOF2 was reverted by blocking the expression of
the most abundant novel PKC isozyme found in our
cultures, PKCθ. This result represents another evidence
that supports the role of EOF2 in novel PKC activation,
and neuronal differentiation probably mediated by neur-
egulin release.
Enabling neuronal replacement in injuries with EOF2
Previous studies describe a response of neurogenic
niches to cortical and spinal cord injuries34–38. Most of
these studies show a neurogenic response of the DG and
SVZ together with the absence of newly generated neu-
roblast within the perilesional area in control conditions.
Interestingly, inhibiting ADAM17-mediated release of
TGFα resulted in a neurogenic response within the
perilesional area that produced a large number of new
neurons8. In agreement with these studies, we show in
here that injuries of control mice treated with vehicle
showed none or a very small number of neuroblasts. The
importance of our work is that we find a considerable
number of newborn neurons in injuries of mice treated
(see figure on previous page)
Fig. 7 Intranasal administration of EOF2 induce neuroblast migration from the neurogenic regions to the damage area. a Scheme of BrdU
administration. Experimental procedure followed to label proliferating neural precursors with BrdU exclusively in neurogenic niches and not in the
injured area: mice received BrdU injections on days 6, 5 and 4 before performing the cortical injury; then we waited three more days to allow for
complete withdrawal of BrdU from the animal organism. Lesion was performed on day 0. Intranasal EOF2 (5 µM) or only vehicle was administered for
14 days. b Representative confocal microscopy images of the injured cortex of adult mice after bearing cortical lesions and the intranasal
administration of EOF2 or only vehicle processed for the immunohistochemical detection of the proliferation marker BrdU and the neuroblast marker
doublecortin (DCX). The dotted line indicates the limit of the lesion (L) and the scale bar represent 100 µm in the low magnification pictures and
50 µm in the high magnification picture. c Graph shows the number of proliferating cells marked with BrdU per mm3 in the peri-lesional area of the
indicated animal groups. Data shown are the mean ± S.E.M.; n= 6 animals per group. Statistical analysis: *p= 0.0377 in two tailed unpaired Student’s
t test comparing EOF2 with the control. d Quantification of DCX+ cells/mm3 in the peri-lesional area of the indicated animal groups. Data shown are
the mean ±S.E.M.; n= 6 animals per group. Statistical analysis: *p= 0.0012 in two tailed unpaired Student’s t test comparing EOF2 with the control. e
Percentage of BrdU+ cells that co-expressed DCX in the peri-lesional area. Data shown are the mean ± S.E.M.; n= 6 animals per group. Statistical
analysis: *p= 0.0100 in two tailed unpaired Student’s t test comparing EOF2 with the control. f Representative confocal microscopy images of the
injured cortex of adult mice in the previously indicated groups processed for the immunohistochemical detection of the proliferation marker BrdU
and the glial marker GFAP. The dotted line indicates the limit of the lesion (L) and the scale bar represent 100 µm in the low magnification pictures
and 50 µm in the high magnification picture. g Percentage of BrdU+ cells that co-expressed GFAP in the peri-lesional area. Data shown are the mean
± S.E.M.; n= 6 animals per group. Statistical analysis: *p= 0.0214 in two tailed unpaired Student’s t test comparing EOF2 with the control. h Graph
shows the GFAP burden within the peri-lesional area, expressed as a percentage of the total lesion area. No statistically significant differences were
found. Data shown are the mean ± S.E.M.; n= 6 animals per group. Statistical analysis: p= 0.4464 in two tailed unpaired Student’s t test comparing
EOF2 with the control.
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with EOF2. Previous results have identified neuroblasts
migrating from the SVZ towards the site of injury
through the corpus callosum. However, in the absence of
treatments these neuroblasts never reached the injured
site8. This indicated that signaling molecules that lead
neuroblasts towards the injury, need to be released—as
described in Comte et al. 2011, for Galectin-3—to
maintain motility from the SVZ to the olfactory bulb39.
Since neuregulins play a role in neuroblast migration and
survival it was reasonable to test the effect of EOF2 on
migration finding an administration method that allowed
the continuous administration of the compound avoiding
local damage and allowing a more extensive delivery of
EOF2, reaching the DG and SVZ. We used intranasal
delivery, a method that has been successfully used in
previous works40–42. Detection of migrating cells was
possible by using a BrdU labeling strategy in which BrdU
was administered to the mice 6 days prior to inducing the
injury. Using this strategy, we have demonstrated that the
presence of the injury induces migration of BrdU+ cells
from the SVZ but only in mice treated with EOF2 BrdU+
cells migrate from the SVZ reaching the injury. More-
over, in treated mice a considerable number of DCX+
neuroblasts and NeuN+ neurons that co-localize with
Fig. 8 Intranasal administration of EOF2 induces neuronal differentiation in the peri-lesional area after brain injury. a Scheme representing
the experimental procedure followed to label proliferating neural precursors with BrdU exclusively in neurogenic niches and not in the injured area:
mice received BrdU injections on days 6, 5, and 4 before performing the cortical injury; then we waited three more days to allow for complete
withdrawal of BrdU from the animal organism. Lesion was performed on day 0. Intranasal administration of EOF2 (5 µM) or only vehicle was
performed for 14 days. b Representative confocal microscopy images of the injured cortex of adult mice after bearing cortical lesions and the
intranasal administration of EOF2 or only vehicle. The dotted line indicates the limit of the lesion (L) and the scale bar represent 100 µm in the low
magnification pictures and 20 µm in the high magnification pictures. c Graph shows the number of neuronal cells marked with NeuN per mm3 in the
peri-lesional area of the indicated animal groups. Data shown are the mean ± S.E.M.; n= 6 animals per group. Statistical analysis: *p= 0.0339 in two
tailed unpaired Student’s t test comparing EOF2 with the control. d Percentage of BrdU+ cells that co-expressed the neuronal marker NeuN in the
peri-lesional area. Data shown are the mean ± S.E.M.; n= 6 animals per group. Statistical analysis: *p= 0.0411 in two tailed unpaired Student’s t test
comparing EOF2 with the control.
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BrdU were found within the perilesional area 14 dpi
indicating that these neuroblasts had migrated from the
SVZ. The presence of neuroblasts describing a track from
the SVZ through the corpus callosum and cortex and
reaching the lesioned area in treated mice supports this
fact (supplementary fig. S6). An attempt of neuroblast
migration was observed from the SVZ of control mice,
however, no neuroblasts were found within the corpus
callosum, the cortex or around the perilesional area in
these mice. Neuroblasts left the SVZ and reached the
corpus callosum without migrating through it towards
the injury (supplementary fig. S6). After a longer 28-day
treatment with EOF2 around 50% of the BrdU+ cells
found 14 dpi survived. At this stage, a percentage of the
BrdU+ cells had differentiated into mature cholinergic
neurons and a few of them differentiated into
parvalbumin+ GABAergic neurons. The rest of BrdU+
cells, not labeled with ChAT or parvalbumin, may be
neuroblasts, undifferentiated progenitors, glial cells, or
they may have developed a different neuronal phenotype.
In summary, all this indicates that EOF2 facilitated
migration of neuroblasts and that these neuroblasts dif-
ferentiated into mature neurons. Similar results have
been obtained upon reduction of TGFα release by
ADAM17 inhibition8. Therefore, it is feasible that the
capacity of EOF2 to favor neuregulin release over TGFα
is promoting neurogenesis in injuries.
Conclusion
In conclusion, we are reporting in here the discovery of
EOF2 as a new non-tumorigenic specific activator of
novel PKC isozymes, with the capacity to induce neuro-
genesis in brain injuries. We have unraveled its mechan-
isms of action mediated by its capacity to activate novel
PKC releasing neuregulin. In addition, we have used an
effective, noninvasive intranasal administration method of
this compound for its effective delivery in the mouse brain
promoting neuronal replacement in injuries. Our work
highlights the role of novel PKC, as targets and for an
effective treatment to compensate neuronal loss in
damaged brain areas, being of special relevance in the
development of new drugs to use in brain injury regen-
eration strategies.
Materials and methods
Reagents
The lathyrane EOF2 3,8,12-tri-O-acetyl-7-O-(4-meth-
oxyphenyl) acetylingol; CAS number 2230806–06–9; was
isolated and purified in our laboratory, as described pre-
viously43,44. Briefly, purification by semipreparative HPLC
was performed with a Hitachi/Merck L-6270 apparatus
equipped with a differential refractometer detector (RI-
7490). A LiChrospher® Si 60 (10 μm) LiChroCart®
(250 mm× 10mm) column was used in isolation
experiments. Silica gel (Merck) was used for column
chromatography. TLC was performed on Merck Kieselgel
60 F254, 0.25 mm thick. Infrared spectra were recorded
on a FT-IR spectrophotometer and reported as wave-
numbers (cm−1). 1H and 13C NMR measurements were
obtained on a 400MHz spectrometer with SiMe4 as the
internal reference. Chemical shifts were referenced to
CDCl3 (δH 7.25, δC 77.0), NMR assignments were made
by a combination of 1D and 2D techniques. Multiplicities
are described using the following abbreviations: s= sing-
let, d= doublet, t= triplet, q= quartet, m=multiplet,
and br= broad. High-Resolution Mass Spectrometry was
performed with a QTOF mass spectrometer in positive
ion ESI mode.
The commercial PKC activators PMA (13-O-acetyl-12-
O-tetradecanoylphorbol, also known as TPA) and pros-
tratin (13-O-acetyl-12-deoxyphorbol) were both pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). The
general PKC inhibitor bisindolylmaleimide I (also known
as GF109203X, GFX or Gö6850) and the classical PKC
inhibitor Gö6976 were from Calbiochem (Millipore, Bill-
erica, MA, USA), and were added to the cells at final
concentrations of 5 µM and 1 µM, respectively. Stock
solutions of all PKC interacting compounds were pre-
pared in DMSO and pre-diluted in culture medium before
addition to cell cultures. When cultures were co-treated
with PKC inhibitors and activators, PKC inhibitors were
added to the cells 30 min before addition of PKC activa-
tors. Specific small interference RNAs (siRNAs) were
from Thermo Scientific Dharmacon (Lafayette, CO, www.
dharmacon.com).
Other products, unless otherwise indicated, were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA).
Animal subjects
CD1 male mice were used throughout this study. Ani-
mals were housed under controlled conditions of tem-
perature (21–23 °C) and light (LD 12:12) with free access
to food (AO4 standard maintenance diet, SAFE, Épinay-
sur-Orge, France) and water. Care and handling of ani-
mals were performed according to the Guidelines of the
European Union Council (2010/63/EU), and the Spanish
regulations (65/2012 and RD53/2013) for the use of
laboratory animals. All studies involving animals are
reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals45,46.
Only male mice were used in this work. The total
number of animals used was: 24 2-month old adult mice
and 150 7-day old pups. The number of animals used in
each experiment was determined based on previous
studies22,29,47.
Adult male mice were randomized during the first week
after birth by cross fostering and male were used at the
age of 2 months.
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The protocol used has been authorized by the Ethics
Committee of the “Consejería de Agricultura, Pesca y
Desarrollo Cultural de la Junta de Andalucía”, Spain with
the approval number 30/03/2016/038.
SVZ cell isolation and culture
NPC were isolated from the SVZ of 7-day postnatal (P7)
mice following the same procedure described before48,
and were cultured as described elsewhere49. The sacrifice
of P7 mice was done by decapitation without anesthesia,
and six pups were used for each independent culture. EGF
(20 ng/ml, from GIBCO) and bFGF (10 ng/ml; from
PeproTech, Frankfurt, Germany) were used for culture
expansion, but only bFGF was present in most experi-
mental settings, unless otherwise indicated.
Cloning of human neuregulin and TGFα cDNA fused to GFP
and Cherry
Full-length cDNA encoding the membrane-bound iso-
form of human pro-neuregulin-1 β1-type (NRG1, NCBI
reference sequence: NP_039250.2) with mCherry cDNA
inserted between nucleotides 93 and 94 of NRG1 open
reading frame was cloned into pEGFP-N1 to add EGFP
cDNA to the 3′ end. Construct was synthesized by Gen-
eCust (Boynes, France) to generate the mCherry-NRG1-
GFP construct. The mCherry-TGFα-GFP construct con-
taining the human transforming growth factor alpha
(TGFA, NCBI reference sequence: NM_003236.4), con-
taining mCherry cDNA between nucleotides 126 and 127
of TGFA was built using the same strategy and synthe-
sized by GeneCust (Boynes, France).
HEK293T cultures and transfection
HEK293T cells were obtained from ATCC (Manassas,
VA, USA). They were cultured in DMEM at 37 °C and 5%
CO2 (Thermo Fisher Scientific, Inc., Rockford, IL, USA),
supplemented with fetal bovine serum (10%), 1× Gluta-
MATM-I (Thermo Fisher Scientific, Inc., Rockford, IL,
USA) and penicillin/streptomycin (1%). Cells were pas-
saged, seeded, and allowed to attach for 24 h. Lipofecta-
mine 2000 (Invitrogen; Carlsbad, CA, USA) was used for
transfection of these plasmids. Afterwards, medium was
changed to eliminate Lipofectamine. After an overnight
incubation, the cells were starved for at least 30 min in
serum-free Fluorobrite DMEM (Thermo Fisher Scien-
tific) containing 1% P/S, 0.25% bovine serum albumin,
and 1× GlutaMAXTM-I. and cells were used either in
time-lapse or fluorescence experiments. Control experi-
ments were performed to make sure that the 3.5 h serum
starvation did not affect cell viability. The percentages of
viable transfected cells in serum starved vs non-starved
were 95.12 ± 0.73 vs 94.97 ± 0.5, indicating that serum
deprivation for 3.5 h did not exert an effect on cell
viability.
Cell viability assays
Cells from neurospheres were seeded at a density of
20000 cells/mL, and cultured in the absence or presence
of specific treatments and left for 72 h. Then, cells were
detached and mixed with trypan blue [0.04% wt/vol in
phosphate-buffered saline (PBS)]. Hek293 cells were see-
ded at a density of 200000 cells/mL and cultured as
indicated in the above section. Then cells were detached
from the surface and mixed with trypan blue [0.04% wt/
vol in phosphate-buffered saline (PBS)]. Nonviable cells
(those including the trypan blue dye) and viable cells
(those excluding trypan blue) were counted using a
hemocytometer under an inverted microscope and were
expressed as percentage of the total number of cells.
Samples were coded and blinded quantifications were
done in five independent experiments; each of these five
independent experiments was performed in triplicate.
Experiments were performed and quantified by different
persons.
In vitro time-lapse experiments
Transfected HEK293T cells were plated in 35 mm high
µ–dishes (Ibidi, Munich, Germany). Cells were treated
with EOF2 or inhibitors, as described in the results and
figure legends. Time-lapse assays were performed with a
Zeiss Axio Observer.Z1-Inverted Microscope, using a
plan-apochromat 40× / 0.95 Korr M27 air objective lens.
Images of transfected cells were obtained every 1 min.
Captured images were processed using ZEN lite software
and the efficiency of NRG1 and TGFα cleavage deter-
mined by analyzing the mCherry/GFP fluorescence
intensity over the entire cell areas. The mCherry/GFP
ratios were calculated and normalized to the average ratio
measured before stimulation with EOF2 using the
Microsoft Excel software. Ratiometric images were built
using ImageJ software, after background subtraction, the
mCherry/GFP image was calculated dividing mCherry
channel by the GFP channel. For each pixel, a pseudo-
color scale is used for coding the ratio.
Fluorescence analysis of mCherry-fused TGFα or
neuregulin in the culture medium of HEK293T
Transfected HEK293T cells were plated in Costar® 12-
well cell culture microplate in 1 mL volume of culture
medium. Upon treatment with the EOF2 and/or inhibi-
tors, 50 μL aliquots of culture medium were removed at
30, 60, and 180 min and specific mCherry fluorescence
was measured using the culture medium of non-
transfected cells as blank. Then, cells were washed with
PBS, scratched from the surface of the plates and GFP
fluorescence signal of the whole cells for each condition
was determined using non-transfected cells as blank.
Fluorescence of non-treated transfected cells was used as
control. All fluorescence experiments were done using
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Costar® 96-well black polystyrene plates and a BioTek™
Synergy™ Mx Monochromator-Based MultiMode Reader.
Interference fluorescence from the culture media was
minimized by the optimization of the detection para-
meters: mCherry: excitation 587 nm, emission 610 nm;
GFP: excitation 488 nm, emission 510 nm. Positive con-
trols of TGFα and NRG1 shedding, after classical PKC
activation were done previously using PMA and
inhibitors.
PKC kinase activity assay
Neurospheres were disaggregated and 20,000 single
cells were seeded per well. Treatments (5 μM EOF2 or
vehicle) were added for 1 h prior to cell centrifugation
(200 g, 5 min) and lysis. Inhibitors were added 30 min
before the addition of the treatments. Protein content was
measure in the lysates using the BCA method (Thermo
Fisher Scientific, Rockford, IL, USA), and 1.5 μg of crude
protein was used per assay. The amount of PKC kinase
activity was measured in each sample using the PKC
Kinase Activity Assay Kit (Abcam, Cambridge, U.K.; cat.
No. ab139437), following the manufacturer’s instructions.
Positive controls (20–60 ng of purified active PKC sup-
plied by the kit) and blanks (diluent only) were included in
each independent determination. Blanks were subtracted
from measurements before comparisons were made.
Cell culture adhesion, treatment, and transfection
Neurosphere cells were centrifuged, resuspended in
defined medium with growth factors, and seeded. Cell
transfection with specific siRNAs was performed 18 h
after seeding; for this, cells were changed to antibiotic-free
medium and transfected using Lipofectamine 2000, fol-
lowing the manufacturer’s instructions. Lipofectamine
was removed 6 h later, EOF2 was added and cells were
maintained for 48 additional hours before being fixed for
immunocytochemistry.
Immunocytochemistry
Immunostaining for GFAP and β-III-tubulin was per-
formed as previously described29. The primary antibodies
used for this were: mouse monoclonal anti-βIII-tubulin
(1:1000, Cell Signaling Technology, Boston, MA, USA)
and rabbit polyclonal anti-GFAP (1:3000, Dako, Ham-
burg, Germany). The secondary antibodies used were:
donkey anti-rabbit IgG labeled with AlexaFluor® 488
(1:1000) and donkey anti-mouse IgG labeled with Alexa-
Fluor® 594 (1:1000), from Invitrogen (Carlsbad, CA,
USA). Samples were coded before immunostaining and
blinded quantifications of labeled cells were done in nine
independent experiments. Experiments were performed
and quantified by different individuals to avoid subjective
bias during the quantification process. Original fluores-
cence colors have been changed in some of the pictures
shown, using the ImageJ software, to enhance visualiza-
tion of markers.
RNA isolation, reverse transcription and real-time
quantitative PCR
Total RNA isolation from differentiated cells, the
injured and the intact cortex, reverse transcription and
RT-qPCR to relatively quantify the expression of the dif-
ferent isozymes of PKC were performed as previously
described7. The housekeeping transcript used was 18S
rRNA. All PCR reaction within each experiment was run
in duplicates. Amplification specificity was confirmed by
melting-curve analysis of the PCR products. The relative
expression of each mRNA was calculated as 2−ΔCt, where
ΔCt=Ct (target mRNA)−Ct (18S). No signal was
detected in non-template or non-RT controls.
Primer sequences (5´-3´) and annealing temperatures
were the following: for detecting expression of mouse
mRNA levels in neuroespheres we used the following
primers: PKCα, FW: TGAATCCTCAGTGGAATGAGT,
RW: GGTTGCTTTCTGTCTTCTGAA, 55 °C; for PKCβ,
FW:CCCGAAGGAAGCGAGGGCAATGAAG, RW:AG
TTCATCTGTACCCTTCCGCTCTG, 63 °C; for PKCγ,
FW:TGAGAGAGTGCGGATGGGCCCC, RW:GCAGGC
GTCCTGGGCTGGCACC, 65 °C; for PKCδ, FW:GAGGC
CTTGAACCAAGTGACCC, RW:CTTGCCATAGGTCC
AGTTGTTG, 57 °C; for PKCε, FW:CCCATCTGAAGAC
GACCGATCC, RW:CGGTTGTCAAATGACAAGGCC,
60 °C; for PKCθ, FW:CCATGTCACCGTTTCTTCGA
ATC, RW:TCTGCCCATTTTCTGATTCC, 56 °C; for PK
Cη, FW:ATGGCCACGTACCTGAGGCAGC, RW:GGA
CGACGCAGGTGCACACTTGG, 65 °C; for PKCλ, FW:
CGTTGGGAGCTCTGACAATC, RW:ACCTGCTTTTG
CTCCATCATG, 55 °C; for PKCζ, FW:AGGAGAAGAG
TACGGGTTCAGC, RW:GTGTTCATGTCAGGGTTG
TCCG, 57 °C.
For mouse neuregulin and ErbB4 in injuries and SVZ
we used NRG1, FW: CGCTGTTCTGGTCTCATCCG,
RW: GCGGTGGAGTGGAGTGTAAG, 54 °C; for ErbB4,
FW: TACCTCCTCCCATCTACACATCC, RW: CCTCT
GGTATGGTGCTGGTTG, 57 °C.
The primers used for detection of human PKC isozyme
mRNAs from HEK293 are described supplementary
table T1.
Mechanical lesions in brain cortex
Unilateral cortical lesions were performed in the cortex
of the right hemisphere of adult mice anesthetized with an
intraperitoneal injection of a 100 mg/kg ketamine and
20mg/kg xylazine cocktail. Animals were placed in a
stereotaxic frame (Kopf Instruments), and a small cra-
niotomy was performed at +1.4 mm rostral and +1.5 mm
lateral to Bregma. A controlled mechanical lesion was
performed in the underlying primary motor cortex, using
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a manually driven drill (0.7 mm diameter) that was
allowed to penetrate 1 mm below the bone surface. These
injuries reached the corpus callosum without damaging it.
Studies describing neurogenic responses in mechanical
lesions
Mice were injured using the procedure mentioned
above, and were sacrificed at 14 days post-injury (dpi).
Mice were given three intraperitoneal injections of BrdU
(70 mg/kg each) separated by 3 h intervals on the day of
sacrifice. Mice were sacrificed by brain perfusion, and
brains were processed for post-mortem studies as
described below. In the same surgical acts in which
cortical lesions were performed, Alzet osmotic mini-
pumps (Charles Rivers Barcelona, Spain) were implan-
ted subcutaneously in 12 animals and connected to
infusion cannulas (brain kit II, Alzet) whose tips were
placed 0.5 mm deep into the lesion, allowing a con-
tinuous delivery of a 5 µM solution of EOF2 in PBS
(containing 0.4% DMSO) or vehicle (six mice received
EOF2 and six mice received vehicle). Treatments lasted
for 14 days.
Studies describing migration towards mechanical lesions
In a different set of experiments, aimed to study the
migration of progenitors from neurogenic regions
towards the injured area, mice received BrdU injections 6,
5, and 4 days before the injury was performed. This
paradigm allowed for substantial clearance of BrdU and,
therefore, it allowed BrdU labeling of NPC in the SVZ but
not locally in the injured tissue. These mice (vehicle; n= 6
and EOF2-treated; n= 6) were sacrificed on day 14 after
injury. Starting the day of injury, animals were treated
with daily intranasal administrations of a 5 µM solution
of EOF2 or vehicle, until they were sacrificed 14 dpi
(Figs. 7, 8).
Intranasal administration of EOF2
EOF2, was delivered intranasally as previously descri-
bed40–42. Treatments were administered manually while
the animal was placed in a standing position with an
extended neck as previously described42. 18 µL of each
solution 5 µM EOF2, or vehicle was delivered over both
nasal cavities alternating 3 µL/each using a micropipette.
Mouse was maintained in such position for ten additional
seconds to ensure all fluid was inhaled.
In all experiments, mice were coded, treatment (vehicle
or EOF2) was assigned randomly to code numbers and
applied. In addition, blind quantifications were performed
to avoid subjective biases.
Immunohistochemistry
Brain processing and immunohistochemical detection
of the proliferation marker BrdU, the astrocyte and neural
stem cell marker GFAP, the neural progenitor cell marker
nestin, the early neuronal differentiation marker dou-
blecortin (DCX), and the mature neuron maker NeuN
were performed as previously described49.
Primary antibodies used were mouse monoclonal
anti-BrdU (1:100) from Dako (Hamburg, Germany) or
rat monoclonal anti-BrdU (1:100) from Abcam (Cam-
bridge, UK), mouse polyclonal anti-GFAP both from
Cell Signaling (Beverly, MA, USA), goat polyclonal anti-
DCX (1:500), goat polyclonal anti-nestin (1:500), and
mouse monoclonal anti-NeuN (1:100) all of them from
Abcam (Cambridge, UK); goat anti-ChAT, polyclonal,
1:100, Merk Millipore (Billerica, MA, USA) mouse anti-
parvalbumin, monoclonal, 1:100, Merk Millipore (Bill-
erica, Ma, USA). Secondary antibodies used were Alexa
Fluor 488 donkey anti-mouse, Alexa Fluor 594 donkey
anti-mouse, Alexa Fluor 405 goat anti-mouse, Alexa
Fluor 594 donkey anti-rat, Alexa Fluor 488 donkey anti-
rabbit, Alexa Fluor 594 donkey anti-rabbit and Alexa
Fluor 594 donkey anti-goat (all at 1:1000, from
Life Tech).
Quantification of neurogenesis in brain sections
SVZ cells positive for BrdU, DCX, GFAP, NeuN, and
nestin were estimated as previously described29,49.
Positive cells were counted throughout the entire
perilesional area or lateral and laterodorsal walls of the
lateral ventricles (where the SVZ NPC are located) in
every fifth section; 14–16 sections per brain where
analyzed under fluorescence microscopy at ×20 mag-
nification. A confocal microscope (OLYMPUS FV1000)
was used to take images from triple-labeled brain sec-
tions. Mice were coded depending on the treatment and
quantification of cells in brain slices was done in blin-
ded analysis.
Statistical analysis
The data and statistical analysis comply with the
recommendations on experimental design and analysis in
pharmacology50. Statistical analysis was performed using
the computer program IBM SPSS Statistics 22. Normal
distribution of the data was first analyzed using a
Shapiro–Wilks test. Then, a Brown Forsythe test was
performed to test the equality of variances. Afterwards,
when more than one treatment group were compared,
statistical analyses were performed using one-way
ANOVA followed by a post-hoc Bonferroni’s test unless
otherwise indicated. A Student’s t test was used when only
one treatment group was compared with the control.
Differences were considered significant at values of p <
0.05. In general, sample size used in statistical analysis
were n= 6 for in vivo experiments and n= 5–9 for
in vitro experiments. Sample sizes were chosen based on a
previous works related to this one8,22,29,47.
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